tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

AU:PAR Stock Latest News

Paradigm’s PPS Shows Sustained Clinical and Structural Benefits in Canine Osteoarthritis Study
Company AnnouncementsParadigm’s PPS Shows Sustained Clinical and Structural Benefits in Canine Osteoarthritis Study
10d ago
Paradigm Strikes AVet Licensing Deal for Novel Oral Veterinary Osteoarthritis Drug
PremiumCompany Announcements
Paradigm Strikes AVet Licensing Deal for Novel Oral Veterinary Osteoarthritis Drug
12d ago
Paradigm Biopharmaceuticals Director Converts Options Into Shares
PremiumCompany Announcements
Paradigm Biopharmaceuticals Director Converts Options Into Shares
17d ago
Paradigm Biopharmaceuticals Seeks ASX Quotation for Additional Ordinary Shares
PremiumCompany Announcements
Paradigm Biopharmaceuticals Seeks ASX Quotation for Additional Ordinary Shares
18d ago
Paradigm Biopharmaceuticals Seeks ASX Quotation for Additional Ordinary Shares
PremiumCompany Announcements
Paradigm Biopharmaceuticals Seeks ASX Quotation for Additional Ordinary Shares
22d ago
Paradigm Expands Global Phase 3 Knee Osteoarthritis Trial as Peer-Reviewed Data Bolster iPPS Case
PremiumCompany AnnouncementsParadigm Expands Global Phase 3 Knee Osteoarthritis Trial as Peer-Reviewed Data Bolster iPPS Case
22d ago
Paradigm Biopharmaceuticals Seeks ASX Quotation for Additional Ordinary Shares
Premium
Company Announcements
Paradigm Biopharmaceuticals Seeks ASX Quotation for Additional Ordinary Shares
25d ago
Paradigm Biopharmaceuticals Seeks ASX Quotation for Nearly 5 Million New Shares
Premium
Company Announcements
Paradigm Biopharmaceuticals Seeks ASX Quotation for Nearly 5 Million New Shares
1M ago
Paradigm Biopharmaceuticals Flags February 2026 Expiry of 97 Million PAROA Options
PremiumCompany Announcements
Paradigm Biopharmaceuticals Flags February 2026 Expiry of 97 Million PAROA Options
1M ago
Paradigm Nears 25% Recruitment Milestone in Pivotal Knee Osteoarthritis Phase 3 Trial
PremiumCompany Announcements
Paradigm Nears 25% Recruitment Milestone in Pivotal Knee Osteoarthritis Phase 3 Trial
2M ago
Paradigm Biopharmaceuticals’ AGM Resolutions Passed Successfully
PremiumCompany Announcements
Paradigm Biopharmaceuticals’ AGM Resolutions Passed Successfully
3M ago
Paradigm Biopharmaceuticals Secures Additional Funding Through Convertible Notes
PremiumCompany Announcements
Paradigm Biopharmaceuticals Secures Additional Funding Through Convertible Notes
3M ago
Paradigm Biopharmaceuticals Issues 5 Million Convertible Notes
PremiumCompany AnnouncementsParadigm Biopharmaceuticals Issues 5 Million Convertible Notes
3M ago
Paradigm Biopharmaceuticals Secures Funding for Global Clinical Expansion
Premium
Company Announcements
Paradigm Biopharmaceuticals Secures Funding for Global Clinical Expansion
3M ago
Paradigm Biopharmaceuticals Announces Change in Substantial Shareholder Status
Premium
Company Announcements
Paradigm Biopharmaceuticals Announces Change in Substantial Shareholder Status
3M ago
Paradigm Biopharmaceuticals Expands Global Phase 3 Trial with New Sites
PremiumCompany Announcements
Paradigm Biopharmaceuticals Expands Global Phase 3 Trial with New Sites
3M ago
Paradigm Biopharmaceuticals Issues 3 Million Unlisted Options
PremiumCompany Announcements
Paradigm Biopharmaceuticals Issues 3 Million Unlisted Options
4M ago
Paradigm Biopharmaceuticals Announces 2025 Annual General Meeting Details
PremiumCompany Announcements
Paradigm Biopharmaceuticals Announces 2025 Annual General Meeting Details
4M ago
Paradigm Biopharmaceuticals Expands Market Presence with New Securities Quotation
PremiumCompany Announcements
Paradigm Biopharmaceuticals Expands Market Presence with New Securities Quotation
5M ago
Paradigm Biopharmaceuticals Advances Phase 3 iPPS Trial for Knee Osteoarthritis
PremiumCompany AnnouncementsParadigm Biopharmaceuticals Advances Phase 3 iPPS Trial for Knee Osteoarthritis
5M ago
Paradigm Biopharmaceuticals Secures Shareholder Approval for Strategic Financial Moves
Premium
Company Announcements
Paradigm Biopharmaceuticals Secures Shareholder Approval for Strategic Financial Moves
5M ago
Paradigm Biopharmaceuticals Sets AGM Date and Director Nomination Deadline
Premium
Company Announcements
Paradigm Biopharmaceuticals Sets AGM Date and Director Nomination Deadline
5M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >